Information de reference pour ce titreAccession Number: | 00002591-202002290-00038.
|
Author: | Xu, Xiao-Wei physician 1; Wu, Xiao-Xin physician 1; Jiang, Xian-Gao physician 2; Xu, Kai-Jin physician 1; Ying, Ling-Jun physician 3; Ma, Chun-Lian physician 4; Li, Shi-Bo physician 5; Wang, Hua-Ying physician 6; Zhang, Sheng physician 7; Gao, Hai-Nv professor 8; Sheng, Ji-Fang professor 1; Cai, Hong-Liu physician 1; Qiu, Yun-Qing professor 1; Li, Lan-Juan professor 1
|
Institution: | (1)State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, 310003, China (2)Department of Infectious Disease, Wenzhou Central Hospital, Wenzhou, Zhejiang Province, China (3)Department of Infectious Disease, Taizhou Enze Medical Centre (Group), Enze Hospital, Taizhou, Zhejiang Province, China (4)Department of Infectious Disease, First People's Hospital of Wenling, Wenling, Zhejiang Province, China (5)Department of Infectious Disease, Affiliated Zhoushan Hospital, Wenzhou Medical University, Zhoushan, Zhejiang Province, China (6)Department of Respiratory and Critical Care Medicine, Yinzhou People's Hospital, Affiliated Yinzhou Hospital, College of Medicine, Ningbo University, Ningbo City, Zhejiang Province, China (7)Department of Infectious Disease, Taizhou Hospital, Taizhou, Zhejiang Province, China (8)Department of Infectious Disease, ShuLan (Hangzhou) Hospital affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang Province, China
|
Title: | Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.[Miscellaneous Article]
|
Source: | BMJ. 368:m606, February 29, 2020.
|
Abstract: | OBJECTIVE: To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).
DESIGN: Retrospective case series.
SETTING: Seven hospitals in Zhejiang province, China.
PARTICIPANTS: 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection. Data were collected from 10 January 2020 to 26 January 2020.
MAIN OUTCOME MEASURES: Clinical data, collected using a standardised case report form, such as temperature, history of exposure, incubation period. If information was not clear, the working group in Hangzhou contacted the doctor responsible for treating the patient for clarification.
RESULTS: Of the 62 patients studied (median age 41 years), only one was admitted to an intensive care unit, and no patients died during the study. According to research, none of the infected patients in Zhejiang province were ever exposed to the Huanan seafood market, the original source of the virus; all studied cases were infected by human to human transmission. The most common symptoms at onset of illness were fever in 48 (77%) patients, cough in 50 (81%), expectoration in 35 (56%), headache in 21 (34%), myalgia or fatigue in 32 (52%), diarrhoea in 3 (8%), and haemoptysis in 2 (3%). Only two patients (3%) developed shortness of breath on admission. The median time from exposure to onset of illness was 4 days (interquartile range 3-5 days), and from onset of symptoms to first hospital admission was 2 (1-4) days.
CONCLUSION: As of early February 2020, compared with patients initially infected with SARS-Cov-2 in Wuhan, the symptoms of patients in Zhejiang province are relatively mild.
(C) 2020 BMJ Publishing Group Ltd
|
References: | 1 WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Jan 11, 2020. https://www.who.int/publications...- ouverture dans une nouvelle fenêtre.
2 Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle. J Med Virol 2020;published online 16 January. 10.1002/jmv.25678.
3 Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol 2020;published online 22 January. 10.1002/jmv.25682.
4 de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013;87:7790-2. 10.1128/JVI.01244-13.
5 Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20. 10.1056/NEJMoa1211721.
6 Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;published online 30 January. 10.1016/S0140-6736(20)30251-8.
7 WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). November, 2019. https://www.who.int/emergencies/...- ouverture dans une nouvelle fenêtre (accessed Jan 19, 2020).
8 Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;. 10.1007/s11427-020-1637-5.
9 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;published online 24 January. 10.1016/S0140-6736(20)30183-5.
10 Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;Published online January 24. 10.1016/S0140-6736(20)30154-9.
11 World Health Organization. Novel Coronavirus (2019-nCoV). Situation report-5. 25 January 2020. www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d_4.
12 www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11811/202001/P020200127544648420736.pdf (In Chinese).
13 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;published online 30 January. 10.1016/S0140-6736(20)30211-7.
14 Kim KH, Tandi TE, Choi JW, Moon JM, Kim MS. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect 2017;95:207-13. 10.1016/j.jhin.2016.10.008.
15 WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/...- ouverture dans une nouvelle fenêtre Jan 27, 2020).
16 Chu CM, Cheng VC, Hung IF, et al. HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. [published Online First: 2004/02/27]. Thorax 2004;59:252-6. 10.1136/thorax.2003.012658.
|
Language: | English.
|
Document Type: | RESEARCH.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0959-8138
|
NLM Journal Code: | 8900488, bmj, 101090866
|
DOI Number: | https://dx.doi.org/10.1136/bmj.m...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|